Please login to the form below
gene-editing
This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.
FDA starts speedy review of Novartis’ sickle cell antibody
Hope of a long-term cure for the disease lies with gene therapy, and there has been encouraging progress on that front as well. ... Meanwhile, a CRISPR-based gene-editing therapy is in development at CRISPR Therapeutics and Vertex, with trials of the
Latest news
-
GSK joins forces with Doudna’s CRISPR lab
New recruit Chris Miller will head GSK's functional genomics push. GlaxoSmithKline’s research chief Hal Barron is deepening its investment in cutting-edge science via a new CRISPR gene-editing ... The university’s Laboratory of Genomics Research (LGR)
-
Vertex eyes Duchenne market with Exonics, CRISPR deals
Biotech has gene-editing expertise. Vertex Pharma has agreed a pair of deals to build a position in gene-editing therapeutics for diseases like Duchenne muscular dystrophy. ... That deal also focuses on gene-editing technology directed at DMD and DM1.
-
Poseida gets Novartis backing for myleoma CAR-T challenger
Poseida’s suite of proprietary gene editing technologies include the piggyBac DNA Modification System, Cas-CLOVER and TAL-CLOVER site-specific nucleases and Footprint-Free Gene Editing. ... It is being manufactured using the firm’s Cas-CLOVER site
-
Sanofi exits R&D pact with Alnylam on rare disease
Sanofi and Alnylam started working together on gene-silencing therapies in 2014, with the French drugmaker’s rare disease unit Genzyme making a $700m investment in the RNA interference specialist and ... The French drugmaker is also working on
-
Sangamo surges on data for haemophilia A gene therapy
nuclease (ZFN) gene-editing platform for rare disease Hunter syndrome. ... reduces risk in the company’s other gene therapy programmes which include candidates for Fabry disease, amyotrophic lateral sclerosis and Huntington’s disease.
More from news
Approximately 5 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... These include pipeline gene-editing therapies from Sanofi and luspatercept from Celgene to name but a few, although
-
Vertex: a vision of treating all CF patients worldwide draws closer
A gene therapy cure for all the world’s CF patients would be a truly remarkable achievement. ... These include alpha-1 antitrypsin deficiency and focal segmental glomerulosclerosis. It’s also working with CRISPR Therapeutics on phase 1/2 clinical
-
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... Meanwhile, CRISPR isn’t the only gene-editing technology being used in human therapeutics, although its devotees claim it is the simplest, easiest and
-
Cutting through the noise: CRISPR
Gene editing as a therapeutic tool has ignited an explosion of excitement within the industry over the past few years: the science fiction concept of being able to simply remove and ... With an array of such tools in play, scientists seem to be on the
-
Bluebird Bio: on the cusp of a gene therapy revolution
That means gene products hitting that Glybera price of $1m are, for now at least, unlikely. ... CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with
More from intelligence
Approximately 2 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “With his deep understanding of the gene-editing landscape and extensive
-
Marc Becker joins CRISPR Therapeutics
He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
'Fake news': battling misinformation in healthcare
After reading this headline, it’s easy to assume that some form of gene editing has led to a cure for HIV. ... Should you read on, you would also discover that gene-editing was in no way used in this treatment.
-
Random42 Partner with MedCity for BioJapan 2018
J. Leading UK health scientists, universities and national research institutions will provide insight into the UK life sciences sector, and their work in ageing, gene editing and artificial intelligence.
-
Training the next generation of biotech leaders
Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... It’s such a disruptive advancement – it’s just incredible to think it has all been made feasible
-
Perspective on biotech
The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
